Recent 8-K filings for CPHI
Highest-materiality recent filing
China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP
- SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
- China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.
-
CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares
Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.
-
China Pharma subsidiary acquires Ipragliflozin patent for $9.8M in stock
Hainan Helpson enters Technology Transfer Agreement to acquire Ipragliflozin tablet patent from Juan Zhang.
-
China Pharma subsidiary to acquire captopril microcapsule patent for $6.3M in stock
Hainan Helpson subsidiary to receive Captopril microcapsule invention patent and preparation method from Lijie Tang.
-
China Pharma rescinds Dec 12 securities purchase agreement; deal void ab initio
On Dec 23, 2024, company and an unnamed investor agreed to rescind the Dec 12 securities purchase agreement.
-
SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
-
China Pharma announces 1-for-5 reverse stock split effective March 6, 2024
Reverse split at 1-for-5 ratio, effective March 6, 2024; every 5 pre-split shares convert to 1 post-split share.
-
NYSE American warns China Pharma of delisting; avg price below $0.20, cure by March 2024
On Sep 27, 2023, NYSE American notified CPHI of noncompliance: 30-day avg stock price below $0.20.
-
China Pharma Holdings extends convertible note maturity to May 2024 with Streeterville Capital
Maturity extended from November 2021 note to May 19, 2024, with an extension fee of 2% of the outstanding balance.
-
Resolved low selling price deficiency via 1-for-10 reverse stock split on March 6, 2023.
-
China Pharma receives NYSE American deficiency notice for equity shortfall
Stockholders' equity of $2.8M as of Sept 30, 2022 below the $4.0M minimum required by Section 1003(a)(ii).
-
Average stock price below $0.20 over 30 days as of Sept 22, 2022 triggers continued listing noncompliance.
-
CPHI receives NYSE American delisting notice for insufficient stockholders' equity
Stockholders' equity was $5.3M as of March 31, 2022, below the $6.0M minimum required under Section 1003(a)(iii).
-
China Pharma issues 1.76M shares to CEO to offset accrued compensation; grants option to director
Compensation Committee approved 1,760,000 shares to CEO Zhilin Li at $0.67/share to partially offset $1,666,706 in accrued unpaid cash compensation.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event other_material